Editor’s Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

The editors are publishing this note to alert readers to concerns about this article (1). The authors informed the journal that the image representing EGFR expression in H1650 cells treated with erlotinib in Fig. 1C was mistakenly flipped and also used in Fig. 3A to represent EGFR expression in H1650 cells treated with the same doses of erlotinib for the same period of time. In Fig. 3D, the Western blot representing Bim expression in PC9^PTENkd cells was spliced to remove an empty lane between the third and fourth lane; however, this was not noted in the manuscript. The authors regret these errors.